- Home
- CRDL vs ONCY Comparison
CRDL vs ONCY Comparison
Compare CRDL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- ONCY
- Stock Information
- Founded
- CRDL 2017
- ONCY 1998
- Country
- CRDL Canada
- ONCY Canada
- Employees
- CRDL N/A
- ONCY N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- CRDL Health Care
- ONCY Health Care
- Exchange
- CRDL Nasdaq
- ONCY Nasdaq
- Market Cap
- CRDL 90.4M
- ONCY 89.7M
- IPO Year
- CRDL N/A
- ONCY 1999
- Fundamental
- Price
- CRDL $1.22
- ONCY $1.21
- Analyst Decision
- CRDL Strong Buy
- ONCY Strong Buy
- Analyst Count
- CRDL 2
- ONCY 5
- Target Price
- CRDL $9.00
- ONCY $5.00
- AVG Volume (30 Days)
- CRDL 859.1K
- ONCY 847.9K
- Earning Date
- CRDL 11-13-2025
- ONCY 11-11-2025
- Dividend Yield
- CRDL N/A
- ONCY N/A
- EPS Growth
- CRDL N/A
- ONCY N/A
- EPS
- CRDL N/A
- ONCY N/A
- Revenue
- CRDL N/A
- ONCY N/A
- Revenue This Year
- CRDL N/A
- ONCY N/A
- Revenue Next Year
- CRDL N/A
- ONCY N/A
- P/E Ratio
- CRDL N/A
- ONCY N/A
- Revenue Growth
- CRDL N/A
- ONCY N/A
- 52 Week Low
- CRDL $0.77
- ONCY $0.33
- 52 Week High
- CRDL $2.24
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- CRDL 63.48
- ONCY 49.21
- Support Level
- CRDL $1.01
- ONCY $1.10
- Resistance Level
- CRDL $1.38
- ONCY $1.26
- Average True Range (ATR)
- CRDL 0.08
- ONCY 0.07
- MACD
- CRDL 0.02
- ONCY -0.01
- Stochastic Oscillator
- CRDL 58.60
- ONCY 43.40
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.